BR9809398A - Quinazolinonas que inibem a farnesil transferase - Google Patents
Quinazolinonas que inibem a farnesil transferaseInfo
- Publication number
- BR9809398A BR9809398A BR9809398-3A BR9809398A BR9809398A BR 9809398 A BR9809398 A BR 9809398A BR 9809398 A BR9809398 A BR 9809398A BR 9809398 A BR9809398 A BR 9809398A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- alkyloxy
- hydrogen
- halo
- optionally substituted
- Prior art date
Links
- 102000007317 Farnesyltranstransferase Human genes 0.000 title abstract 2
- 108010007508 Farnesyltranstransferase Proteins 0.000 title abstract 2
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004951 trihalomethoxy group Chemical group 0.000 abstract 2
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C07D239/82—Oxygen atoms with an aryl radical attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Cosmetics (AREA)
Abstract
Patente de Invenção:<B>"QUINAZOLINONAS QUE INIBEM A FARNESIL TRANSFERASE"<D>. Esta invenção diz respeito aos compostos de fórmula (I), aos sais de adição de ácido farmaceuticamente aceitáveis e as suas formas estereoquimicamente isoméricas, onde a linha pontilhada representa uma ligação opcional; X é oxigênio ou enxofre; R^ 1^ e R^ 2^, cada um independentemente, são hidrogênio, hidróxi, halo, ciano, C~ 1-6~alquila, trihalometila, trihalometóxi, C~ 2-6~alquenila, C~ 1-6~alquilóxi, hidróxiC~ 1-6~alquilóxi, C~ 1-6~alquilóxiC~ 1-6~alquilóxi, C~ 1-6~alquilóxicarbonila, aminoC~ 1-6~alquilóxi, mono- ou di(C~ 1-6~alquil)aminoC~ 1-6~alquilóxi, Ar^ 1^, Ar^ 1^C~ 1-6~alquila, Ar^ 1^óxi, Ar^ 1^C~ 1-6~alquilóxi; ou quando em posições adjacentes, R^ 1^ e R^ 2^representados juntos podem formar um radical bivalente; R^ 3^ e R^ 4^, cada um independentemente, são hidrogênio, halo, ciano, C~ 1-6~alquila; C~ 1-6~alquilóxi, Ar^ 1^oxi, C~ 1-6~alquiltio, di(C~ 1-6~alquil)amino, trihalometila, trihalometóxi; R^ 5^ é hidrogênio, halo, ciano, C~ 1-6~alquila opcionalmente substituída, C~ 1-6~alquilóxicarbonila ou Ar^ 1^; ou um radical de fórmula -OR^ 10^, -SR^ 10^, -NR^ 11^R^ 12^; R^ 6^ é uma porção de imidazolila opcionalmente substituída; R^ 7^ é hidrogênio ou C~ 1-6~alquila, desde que a linha pontilhada não represente uma ligação; R^ 8^ é hidrogênio, C~ 1-6~alquila ou Ar^ 2^CH~ 2~ ou Het^ 1^CH~ 2~; R^ 9^ é hidrogênio, C~ 1-6~alquila, C~ 1-6aquilóxi ou halo, ou R^ 8^ e R^ 9^ representados juntos podem formar um radical bivalene; Ar^ 1^ e Ar^ 2^ são fenila opcionalmente substituída e Het^ 1^ é piridinila opcionalmente substituída; tendo atividade de inibição da farnesiltransferase; a sua preparação, às composições contendo os mesmos e ao seu uso como um medicamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97201259 | 1997-04-25 | ||
| PCT/EP1998/002357 WO1998049157A1 (en) | 1997-04-25 | 1998-04-17 | Farnesyltransferase inhibiting quinazolinones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9809398A true BR9809398A (pt) | 2000-06-13 |
Family
ID=8228267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9809398-3A BR9809398A (pt) | 1997-04-25 | 1998-04-17 | Quinazolinonas que inibem a farnesil transferase |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6177432B1 (pt) |
| EP (1) | EP0977750B1 (pt) |
| JP (1) | JP4308919B2 (pt) |
| KR (1) | KR100520401B1 (pt) |
| CN (1) | CN1094937C (pt) |
| AT (1) | ATE366250T1 (pt) |
| AU (1) | AU738628B2 (pt) |
| BR (1) | BR9809398A (pt) |
| CA (1) | CA2288140C (pt) |
| CZ (1) | CZ296959B6 (pt) |
| DE (1) | DE69838025T2 (pt) |
| ES (1) | ES2289783T3 (pt) |
| HU (1) | HUP0001122A3 (pt) |
| IL (1) | IL130363A (pt) |
| NO (1) | NO317576B1 (pt) |
| NZ (1) | NZ336233A (pt) |
| PL (1) | PL190944B1 (pt) |
| RU (1) | RU2205831C2 (pt) |
| SK (1) | SK146199A3 (pt) |
| TR (1) | TR199902606T2 (pt) |
| WO (1) | WO1998049157A1 (pt) |
| ZA (1) | ZA983504B (pt) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9809398A (pt) * | 1997-04-25 | 2000-06-13 | Janssen Pharmaceutica Nv | Quinazolinonas que inibem a farnesil transferase |
| HRP20000904A2 (en) | 1998-07-06 | 2001-12-31 | Janssen Pharmaceutica Nv | Farnesyl protein transferase inhibitors for treating arthropathies |
| US6284755B1 (en) | 1998-12-08 | 2001-09-04 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6316436B1 (en) | 1998-12-08 | 2001-11-13 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| BR9916827A (pt) | 1998-12-23 | 2001-10-16 | Janssen Pharmaceutica Nv | Derivados de quinolina 1,2-anelados |
| KR20010077400A (ko) * | 2000-02-02 | 2001-08-17 | 성재갑 | 에프타아제 저해제인 엘비42908과 타(他) 항암제와의조합에 의한 항암치료제 |
| SI1255537T1 (sl) * | 2000-02-04 | 2006-10-31 | Janssen Pharmaceutica Nv | Inhibitorji farnezil protein transferaze za zdravljenje raka dojk |
| US6838467B2 (en) | 2000-02-24 | 2005-01-04 | Janssen Pharmaceutica N. V. | Dosing regimen |
| CA2397253A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| US20030022918A1 (en) * | 2000-02-29 | 2003-01-30 | Horak Ivan David | Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| US20030181473A1 (en) * | 2000-02-29 | 2003-09-25 | Palmer Peter Albert | Farnesyl protein transferase inhibitor combinations with taxane compounds |
| US20030212008A1 (en) * | 2000-02-29 | 2003-11-13 | Palmer Peter Albert | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| JP2003525234A (ja) * | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | カンプトテシン化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 |
| AU2001239275A1 (en) * | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| CA2397657A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica Inc. | Farnesyl protein transferase inhibitor combinations with platinum compounds |
| EP1261348A2 (en) * | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| EP1261342A2 (en) * | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations |
| WO2001064195A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| CA2397475A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| JO2361B1 (en) * | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
| JP4974439B2 (ja) * | 2000-09-25 | 2012-07-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体 |
| US7173040B2 (en) | 2000-09-25 | 2007-02-06 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives |
| WO2002024686A2 (en) * | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
| ATE321038T1 (de) | 2000-09-25 | 2006-04-15 | Janssen Pharmaceutica Nv | Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren |
| DE60139080D1 (de) | 2000-11-21 | 2009-08-06 | Janssen Pharmaceutica Nv | Farnesyltransferase hemmende benzoheterocyclische derivate |
| WO2002043733A1 (en) * | 2000-11-28 | 2002-06-06 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease |
| WO2002051835A1 (en) * | 2000-12-27 | 2002-07-04 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
| ES2318000T3 (es) * | 2001-02-15 | 2009-05-01 | Janssen Pharmaceutica Nv | Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos. |
| EA006770B1 (ru) * | 2001-03-12 | 2006-04-28 | Янссен Фармацевтика Н.В. | Способ получения соединений имидазола |
| US20020177575A1 (en) * | 2001-05-04 | 2002-11-28 | Ward Wakeland | Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies |
| EP1458720B1 (en) * | 2001-12-19 | 2009-03-18 | Janssen Pharmaceutica N.V. | 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
| FR2837201A1 (fr) * | 2002-03-18 | 2003-09-19 | Servier Lab | Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ATE364384T1 (de) | 2002-03-22 | 2007-07-15 | Janssen Pharmaceutica Nv | Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren |
| ATE336496T1 (de) | 2002-04-15 | 2006-09-15 | Janssen Pharmaceutica Nv | Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen |
| US20030125268A1 (en) * | 2002-08-28 | 2003-07-03 | Rybak Mary Ellen Margaret | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| JP2007529555A (ja) * | 2004-03-18 | 2007-10-25 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | シヌクレイノパチーを治療する方法 |
| WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
| US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
| EP1744751A4 (en) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES |
| WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| EP1655289A1 (en) * | 2004-11-04 | 2006-05-10 | Embl | Quinazoline derivatives, process for their preparation, their use as antimitotics and pharmaceutical compositions comprising said derivatives |
| EP1815247B1 (en) | 2004-11-05 | 2013-02-20 | Janssen Pharmaceutica NV | Therapeutic use of farnesyltransferase inhibitors and methods of monitoring the efficacy thereof |
| US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
| ES2601503T3 (es) | 2005-04-19 | 2017-02-15 | Novartis Ag | Composición farmacéutica |
| US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
| EP1968591A4 (en) | 2005-12-23 | 2010-02-17 | Link Medicine Corp | TREATMENT OF SYNUCLEINOPATHIES |
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| MX2008013533A (es) | 2006-04-20 | 2009-01-15 | Janssen Pharmaceutica Nv | Compuestos heterociclicos como inhibidores de c-fms cinasa. |
| EP2016070B1 (en) | 2006-04-20 | 2016-01-13 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
| CN101600698B (zh) | 2006-09-11 | 2012-01-11 | 欧加农股份有限公司;药典有限责任公司 | 喹唑啉酮和异喹啉酮乙酰胺衍生物 |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| MX2011005096A (es) * | 2008-11-13 | 2011-11-18 | Link Medicine Corp | Derivados de azaquinolinona y usos de los mismos. |
| ES3031438T3 (en) | 2009-06-25 | 2025-07-08 | Alkermes Pharma Ireland Ltd | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| CA2806112C (en) | 2010-07-28 | 2023-03-21 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
| CN104870454B (zh) | 2012-08-07 | 2020-03-03 | 詹森药业有限公司 | 用于制备杂环酯衍生物的方法 |
| CN107266405A (zh) | 2012-08-07 | 2017-10-20 | 詹森药业有限公司 | 用于制备c‑fms激酶抑制剂的方法 |
| CN103275085B (zh) * | 2013-05-30 | 2015-04-08 | 温州大学 | 一种喹唑啉并喹唑啉酮化合物及其合成方法和用途 |
| EA201890512A1 (ru) * | 2015-08-17 | 2018-09-28 | Кура Онколоджи, Инк. | Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы |
| RS61745B1 (sr) | 2016-11-03 | 2021-05-31 | Kura Oncology Inc | Inhibitori farneziltransferaze za upotrebu u tretiranju kancera |
| WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| CA3092335A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| US20220143006A1 (en) | 2019-03-15 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2002864C (en) * | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
| US5430148A (en) * | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
| WO1994007498A1 (fr) * | 1992-10-07 | 1994-04-14 | Sumitomo Pharmaceuticals Company, Limited | Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale |
| TW321649B (pt) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| BR9809398A (pt) * | 1997-04-25 | 2000-06-13 | Janssen Pharmaceutica Nv | Quinazolinonas que inibem a farnesil transferase |
-
1998
- 1998-04-17 BR BR9809398-3A patent/BR9809398A/pt not_active Application Discontinuation
- 1998-04-17 NZ NZ336233A patent/NZ336233A/xx unknown
- 1998-04-17 PL PL336468A patent/PL190944B1/pl unknown
- 1998-04-17 RU RU99124815/04A patent/RU2205831C2/ru active
- 1998-04-17 ES ES98924161T patent/ES2289783T3/es not_active Expired - Lifetime
- 1998-04-17 HU HU0001122A patent/HUP0001122A3/hu unknown
- 1998-04-17 TR TR1999/02606T patent/TR199902606T2/xx unknown
- 1998-04-17 CA CA002288140A patent/CA2288140C/en not_active Expired - Lifetime
- 1998-04-17 JP JP54656198A patent/JP4308919B2/ja not_active Expired - Lifetime
- 1998-04-17 AT AT98924161T patent/ATE366250T1/de not_active IP Right Cessation
- 1998-04-17 CN CN98804366A patent/CN1094937C/zh not_active Expired - Lifetime
- 1998-04-17 DE DE69838025T patent/DE69838025T2/de not_active Expired - Lifetime
- 1998-04-17 IL IL13036398A patent/IL130363A/en not_active IP Right Cessation
- 1998-04-17 EP EP98924161A patent/EP0977750B1/en not_active Expired - Lifetime
- 1998-04-17 SK SK1461-99A patent/SK146199A3/sk unknown
- 1998-04-17 US US09/403,705 patent/US6177432B1/en not_active Expired - Lifetime
- 1998-04-17 WO PCT/EP1998/002357 patent/WO1998049157A1/en not_active Ceased
- 1998-04-17 KR KR10-1999-7005507A patent/KR100520401B1/ko not_active Expired - Fee Related
- 1998-04-17 AU AU76460/98A patent/AU738628B2/en not_active Expired
- 1998-04-17 CZ CZ0371799A patent/CZ296959B6/cs not_active IP Right Cessation
- 1998-04-24 ZA ZA9803504A patent/ZA983504B/xx unknown
-
1999
- 1999-10-22 NO NO19995169A patent/NO317576B1/no unknown
-
2000
- 2000-10-13 US US09/687,153 patent/US6358961B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9808843A (pt) | Derivados de quinolinona 1,8-anelados inibidores da farnesil transferase substituìdos com imidazóis ligados em n ou em c | |
| NO995169D0 (no) | Farnesyltransferase-inhiberende quinazolinoner | |
| EA199800395A1 (ru) | Производные 2-хинолона, ингибирующие фарнезилтрансферазу | |
| BRPI9809468B8 (pt) | Formulações farmacêuticas contendo voriconazol | |
| DK1392713T3 (da) | Lever-X-receptoragonister | |
| MY114444A (en) | Farnesyl protein transferase inhibiting (imidazol-5-yl) methyl -2-quinolone derivatives | |
| BR0307624A (pt) | Inibidores de histona desacetilase | |
| BG104499A (en) | Retinoic acid mimetic anilides | |
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| BR0011433A (pt) | Imidazoquinolinas substituìdas com sulfonamida e sulfamida | |
| BR9708099A (pt) | Formulações de propofol em microgotìculas. | |
| NO308736B1 (no) | 1,2-difenylpyrrolderivater, farmasøytiske preparater inneholdende disse, og deres anvendelse | |
| PT979244E (pt) | Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem | |
| GR3004114T3 (pt) | ||
| GB1531924A (en) | Carbamylguanidine antimicrobial compounds | |
| BR9812922A (pt) | Isoquinolinas como inibidores de uroquinase | |
| ES2170177T3 (es) | Benzotienilpiperazinas sustituidas, su uso como medicamentos y procedimientos para su preparacion. | |
| BR9810314A (pt) | Derivados de 5-substituìdo-1,2,4-tiadiazolila que inibem de angiogênese | |
| ATE325116T1 (de) | Farnesyltransferasehemmende 4- heterocyclylchinolin- und chinazolinderivate | |
| FR2419675A1 (fr) | Compositions fongicides a base de phosphites d'isothiouronium | |
| BR9811499A (pt) | "derivados da 6-azauracila como inibidores da il-5" | |
| ID23783A (id) | Anti fungi 2.4.4.-trisubstitusi-1,3-dioksolan | |
| ATE434615T1 (de) | Farnesyltransferase hemmende benzoheterocyclische derivate | |
| EP0635496A3 (fr) | Nouveaux dérivés de benzospiroalcène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| ES2134441T3 (es) | Benzonitrilos terapeuticos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |